Dexamethasone Treatment for Covid-19, a Curious Precedent Highlighting a Regulatory Gap

被引：8

作者：

Gozzo, Lucia ^{[1
]}

Longo, Laura ^{[1
]}

Vitale, Daniela Cristina ^{[1
]}

Drago, Filippo ^{[1
,2
,3
]}

机构：

[1] Univ Hosp Catania, Clin Pharmacol Unit, Reg Pharmacovigilance Ctr, Catania, Italy

[2] Univ Catania, Dept Biomed & Biotechnol Sci, Catania, Italy

[3] Univ Catania, Ctr Res & Consultancy HTA & Drug Regulatory Affai, Catania, Italy

来源：

关键词：

dexamethasone; COVID19; drug repurposing; off-label; European Medicines Agency;

D O I：

10.3389/fphar.2020.621934

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

[No abstract available]

引用

页数：5

共 24 条

[1]

AIFA, 2020, CORT NELL TER PAZ AD

[2]

[Anonymous], 2006, Troisieme rapport du Conseil dorientation des retraites: perspectives 2020 et 2050

[3]

[Anonymous], 2020, BMJ BRIT MED J, DOI DOI 10.1136/bmj.m4057. PMID: 33077424

[4]

[Anonymous], 2020, ROLLING UPDATES CORO, P2020, DOI 10.1101/2020.10.15.20209817

[5]

Council Regulation, 1993, Official Journal L, V214, P1

[6]

Di Bella G, 2010, NEUROENDOCRINOL LETT, V31, P7

[7]

EC, 2020, COR COMM SIGNS JOINT

[8]

EC, 2020, EUR COMM SEC EU ACC

[9]

EMA, 2020, EMA END US DEX COV 1

[10]

EMA, 2020, EMA REC APPL MARK AU